DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

Information source: Boryung Pharmaceutical Co., Ltd
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Fimasartan , Amlodipine, Placebo (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Boryung Pharmaceutical Co., Ltd

Official(s) and/or principal investigator(s):
Young Kwan Jeon, Medical Director, Study Director, Affiliation: Boryung Pharmaceutical Co., Ltd

Overall contact:
Sung Hee Lee, Manager, Phone: 82-2-708-8069, Email: shlee07@boryung.co.kr

Summary

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Sitting Diastolic Blood Pressure

Secondary outcome:

Sitting Systolic Blood Pressure

Sitting Diastolic Blood Pressure

Responder ratio

Eligibility

Minimum age: 20 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Subjects who agreed to participate in this study and submitted the written informed consent 2. Subjects aged 20 to 75 years 3. Essential hypertension subjects who are measured more 90mmHg, less than 114mmHg of sitting diastolic blood pressure (SiDBP) at baseline(day 0). 4. Subjects who considered to understand this study , be cooperative, and able to be followed-up whole of the study period. Exclusion Criteria: 1. Severe hypertension patients; more 115mmHg of SiDBP and/or more 185 mmHg of Sitting systolic blood pressure (SiSBP) 2. Patients with secondary hypertension

3. Patients with significant investigations - abnormal renal function (Creatinine more

1. 5 times than upper limit of normal), abnormal liver function (AST, ALT more 2 times than upper normal), moderate fatty lever needed medication

4. Patients with significant investigations - Hypokalemia(Less than 3. 5mmol/L),

Hyperkalemia(exceeded 5. 5mmol/L) 5. Patients with sodium ion or body fluid is depleted and not able to correct 6. Patients with hypotension who has sign and symptom 7. Patients with surgical and medical disease it is able to be affect to absorption, distribution, metabolism, excretion 8. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c > 9%, regimen change of oral hypoglycemic agent, using insulin) 9. Patients with severe heart disease, ischemic heart disease within 6months, peripheral vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary Artery Bypass Graft (CABG) 10. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia 11. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve disease 12. Patients with severe cerebrovascular disease 13. Patients with wasting disease, autoimmune disease, connective tissue disease at present and/or previous. 14. Patients with known severe or malignancy retinopathy 15. Patients with hepatitis B or C or HIV positive reaction 16. Patients who have a story or evidence of alcohol or drug abuse within 2years 17. Patients who are measured the mean difference of mean blood pressure of both arm under SiDBP 10mmHg or SiSBP 20mmHg at screening and baseline visit 18. Patients with history of allergic reaction to any angiotensin II antagonist 19. Patients with any chronic inflammation disease needed to chronic inflammation therapy 20. Patients with the medical histories of malignant tumor within 5years, except local basal cell carcinoma of the skin 21. Childbearing and breast-feeding women 22. Female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods 23. Patients who took medicine within 12 weeks from screening visit or is going on the progress of other clinical trial 24. Subject who are judged unsuitable to participate in this study by investigator

Locations and Contacts

Sung Hee Lee, Manager, Phone: 82-2-708-8069, Email: shlee07@boryung.co.kr

Samsung Medical Center, Seoul, Korea, Republic of; Recruiting
Eun Seok Jeon, Phone: 82-2-3410-0866, Email: esjeon@smc.co.kr
Additional Information

Starting date: August 2011
Last updated: March 26, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017